Sep. 11 at 6:40 PM
Phio Pharmaceuticals Corp. (Nasdaq:
$PHIO ) announced that members of its management team will be available for one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14 to 16, 2026 at the Lotte New York Palace Hotel in New York City. Phio is a clinical-stage biotechnology company whose proprietary INTASYL® siRNA gene-silencing technology is designed to eliminate cancer.
Phio Pharmaceuticals Corp. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/phio-pharmaceuticals
Management will use the meetings in New York to cover the lead clinical program and the priorities set around it:
• Robert Bitterman, President and Chief Executive Officer, and Lisa Carson, Chief Financial Officer, will be available for meetings with investors throughout the conference
• Management will discuss the company's clinical lead candidate PH-762, strategic priorities, and upcoming initiatives designed to support continued execution and long-term value creation
• PH-762 silences the PD-1 gene implicated in various forms of skin cancer, and the company describes it as a potential non-surgical treatment
• The Phase 1b trial of PH-762 evaluated the compound for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma
INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells, and PH-762 is the lead clinical development program among them.
Read the full release: https://phiopharma.com/phio-pharmaceuticals-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference/
A webcast of Phio Pharmaceuticals' presentation is available at: https://journey.ct.events/view/5bf7a12c-0681-4ee5-9849-694423f35dfd
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biopharmaceutical company advancing its proprietary INTASYL siRNA gene silencing technology to eliminate cancer. Learn more at https://phiopharma.com. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com.
B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.
